ASCO 2022 | Skin cancer highlights at ASCO 2022

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, provides his highlights in the field of skin cancer presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. Findings from the phase III RELATIVITY-047 trial (NCT03470922) of relatlimab and nivolumab in melanoma demonstrated superior overall survival rates in the cohort receiving the combination therapy compared to the monotherapy arm. Durable responses were additionally displayed in the 7-year follow-up data from the phase III CheckMate 067 trial (NCT01844505), which assessed nivolumab plus ipilimumab in patients with advanced melanoma. This interview took place at the ASCO 2022 Annual Meeting in Chicago, IL.